Navigation

Researchers at UCD

researcher

Michael Duffy

Professor (Adjunct)

School of Medicine
Clinical Research Centre,
St Vincent's University Hospital
Dublin 4

Tel: 353-1-7165814
Email: michael.j.duffy@ucd.ie

Biography

Professor Michael J (Joe) Duffy has a long, established career in clinical biochemistry practice, research and education and his specific research interests focus on Breast Cancer. After graduating from NUI, Galway and earning a PhD at the University of Manchester, he went on to become a Post Doctorate Fellow in Trinity College Dublin. He is now adjunct Professor in the School of Medicine & Medical Science at University College Dublin, having previously worked as Principal biochemist at St Vincents University Hospital.
 
One of his main contributions is the development of a test for identifying patients with breast cancer who may not need chemotherapy. This test, which involves measurement of the urokinase plasminogen activator (uPA) marker, is now recommended for clinical use by several expert groups including the American Society of Clinical Oncology.
 
His reputation in the field is recognized internationally, having in excess of over 200 publications most of which are cancer-related. In 2012, Professor Duffy was the recipient of the 2012 Abbott Award of the International Society of Oncology and BioMarkers (ISOBM). This award is made annually to investigators who have made an outstanding contribution in the field of basic or clinical oncology.

Professional

Honours and Awards

Year: 2013.
Title: Lifetime Achievement Award
Year: 1997.
Title: Conway Review Medal Lecture
Year: 1993.
Title: National Committee for Biochemistry Award Medal Lecture
Year: 1983.
Title: St Luke's Medal Lecture
Year: 2102.
Title: Abbott Award

Associations

Association: European Group on Tumor Markers (EGTM), Function/Role: Board member
Association: American Association for Cancer Research (AACR), Function/Role: Member
Association: International Society of Oncology and Biomarkers, Function/Role: Board Member
Association: National Academy of Clinical Biochemistry, Function/Role: Chair of committee for preparing guidelines on tumor markers in breast cancer
Association: National Academy of Clinical Biochemistry (USA), Function/Role: Stering committee member for preparing guidelines on tumor markers
Association: European Group on Tumor Markers, Function/Role: Leader of Gastrointestinal Focus Group
     

Conference Contributions

Duffy, MJ (2015) Biomarkers in breast cancer: What is new?. [Invited Lecture], International Society of Biomarkers and Oncology, Cracow , 01-OCT-15 - 05-OCT-15.
Duffy, MJ (2015) Clinical utility of serum tumor biomarkers in postoperative surveillance and monitoring therapy. [Invited Lecture], EuroMedLab Conference, Paris , 21-JUN-15 - 25-JUN-15.
Duffy, MJ (2015) Vitamin D receptor as a target for the treatment of breast cancer. [Invited Lecture], Symposium on Translational Research in Oncology, Dublin , 09-OCT-15 - 10-OCT-15.
Duffy, MJ (2016) How to validate an emerging cancer biomarker. [Invited Lecture], Workshop on Clinical Decision Support Systems for Breast and Prostate Cancer, Focus on Prognostic and Predictive Tools, Dublin , 07-MAR-16 - 08-MAR-16.
               

Publications

 

Book Chapters

Duffy (2015) 'Use of Biomarkers in Screening for Cancer' In: Scatena R (eds). Advances in Experimental Medicine and Biology. Netherlands: Springer. , pp.27-39 Available Online [Details]
Duffy, MJ; Demir, A; Bonfrer, JMJ (2015) 'Role of circulating biomarkers in oncology' In: Schmoll, H-J (eds). European Society of Medical Oncology Handbook. Boca Raton: Taylor and Francis. [Details]
MJ Duffy, M Mullooly, J Crown, PM McGowan (2013) 'The ADAMs: new Therapeutic Targets for Cancer' In: YH Bae, RJ Mrsny, K Park (eds). Cancer Targeted Drug Delivery. New York: Springer. [Details]
Duffy MJ (2012) 'Use of Tumor markers in the Detection and Management of Patients with Colorectal Cancer' In: C H Cho and J Yu (eds). From Inflammation to Cancer: Advances in Diagnosis and Therapy for Gastrointestinal and Hepatological Disease. New Jersey, London, Singapore: World Scientific. , pp.315-330 [Details]
Duffy MJ; (2009) 'Biomarkers in breast cancer: use in aiding diagnosis, determining prognosis and predicting response to therapy' In: Adit Ben-Baruch (eds). Breast Cancer: From Pathogenesis to Potential Therapeutic Modalities. Kerala, India: Transworld Research Network. , pp.211-227 [Details]
Brunner N, Sweep F, Foekens J, Schmitt M, Duffy MJ (2008) 'New Tumor Biomarkers: Practical Considerations Prior to Clinical Application' In: Daoud SS (eds). Cancer Proteomics: From Bench to Bedside. Netherlands: Springer. , pp.189-200 Available Online [Details]
Duffy MJ (2002) 'Proteases in Cancer: Markers of Metastatic Potential and Prognosis' In: Diamindis, Fritsche, Lija, Chan & Schwartz (eds). Tumor Markers: Physiology, Pathobiology, Technology and Clinical Applications. Washington: American Association Of Clinical Chemistry (AACC) Press. [Details]
 

Peer Reviewed Journals

Mullooly M, McGowan P;Crown J;Duffy MJ (2016) 'The ADAMs Family of Proteases as Targets for the Treatment of Cancer'. Cancer biology & therapy, . [DOI] [Details]
Caiazza F, Murray A;Madden SF;Synnott NC;Ryan EJ;O'Donovan N;Crown J;Duffy MJ (2016) 'Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells'. Endocrine-Related Cancer, 23 (4):323-334. [DOI] [Details]
Mullooly M, McGowan PM, Kennedy SA, Madden SF, Crown J, O' Donovan N, Duffy MJ. (2015) 'ADAM10: a new player in breast cancer progression?'. British Journal of Cancer, 113 :945-991. [Details]
S¿¿l¿¿tormos G, Duffy MJ;Othman Abu Hassan S;Verheijen RH;Tholander B;Bast RC;Gaarenstroom KN;Sturgeon CM;Bonfrer JM;Petersen PH;Troonen H;CarloTorre G;Kanty Kulpa J;Tuxen MK;Molina R (2015) 'Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers'. International Journal of Gynecological Cancer, 26 (1):43-51. [DOI] [Details]
Caiazza F, McGowan PM;Mullooly M;Murray A;Synnott N;O'Donovan N;Flanagan L;Tape CJ;Murphy G;Crown J;Duffy MJ (2015) 'Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells'. British Journal of Cancer, 112 (12):1895-1903. [DOI] [Details]
Duffy MJ, Sturgeon CM;Sölétormos G;Barak V;Molina R;Hayes DF;Diamandis EP;Bossuyt PM (2015) 'Validation of new cancer biomarkers: a position statement from the European group on tumor markers'. Clinical Chemistry, 61 (6):809-820. [DOI] [Details]
Duffy MJ (2015) 'Personalized treatment for patients with colorectal cancer: role of biomarkers'. Biomarkers in Medicine, 9 :337-347. [Details]
Duffy MJ, Walsh S, McDermott EW, Crown J. (2015) 'Biomarkers in Breast Cancer: Where Are We and Where Are We Going?'. Advances in Clinical Chemistry, 71 :1-23. [Details]
Duffy MJ, Lamerz R, Haglund C, Nicolini A, Kalousová M, Holubec L, Sturgeon C. (2014) 'Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update'. INT J CANCER, 14 (11):2513-2522. [Details]
Gaule PB, Crown J;O'Donovan N;Duffy MJ (2014) 'cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?'. Expert Opinion on Therapeutic Targets, 18 (9):999-1009. [DOI] [Details]
Duffy MJ, Crown J (2014) 'Monitoring response to therapy in patients with cancer: is circulating DNA the answer?'. Annals of Translational Medicine, 1 (3). [DOI] [Details]
Duffy MJ, Synnott NC, McGowan PM, Crown J, O'Connor D, Gallagher WM. (2014) 'p53 as a target for the treatment of cancer'. Cancer Treatment Reviews, 40 :1153-1160. [Details]
Duffy MJ, Crown J, Mullooly M. (2014) 'ADAM10 and ADAM17: New players in trastuzumab tesistance'. Oncotarget, 30 :10963-10964. [Details]
Duffy MJ, McGowan PM, Harbeck N, Thomssen C, Schmitt M. (2014) 'uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies'. Breast Cancer Research, 16 :428. [Details]
Duffy MJ (2014) 'PSA in screening for prostate cancer: more good than harm or more harm than good?'. Advances in Clinical Chemistry, 66 :1-23. [Details]
Duffy MJ, Crown J (2014) 'Precision Treatment for Cancer: Role of Prognostic and Predictive Markers'. Critical reviews in clinical laboratory sciences, 50 (1):30-45. [Details]
Romagnoli M, Mineva ND, Polmear M, Conrad C, Srinivasan S, Loussouarn D, Barillé-Nion S, Georgakoudi I, Dagg Á, McDermott EW, Duffy MJ, McGowan PM, Schlomann U, Parsons M, Bartsch JW, Sonenshein GE. (2014) 'ADAM8 expression in invasive breast cancer promotes tumor dissemination and metastasis'. EMBO molecular medicine, 6 (2):278-294. [Details]
Duffy Michael (2013) 'Investigation of Molecular Alterations of AKT-3 in Triple Negative Breast Cancer'. Histopathology, . [Details]
Canonici A, Gijsen M;Mullooly M;Bennett R;Bouguern N;Pedersen K;O'Brien NA;Roxanis I;Li JL;Bridge E;Finn R;Siamon D;McGowan P;Duffy MJ;O'Donovan N;Crown J;Kong A (2013) 'Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer'. Oncotarget, 4 (10):1592-1605. [Details]
Pierce A, McGowan PM;Cotter M;Mullooly M;O'Donovan N;Rani S;O'Driscoll L;Crown J;Duffy MJ (2013) 'Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines'. Cancer Biology and Therapy, 14 (6):537-545. [DOI] [Details]
Duffy MJ, Crown J (2013) 'Monitoring response to therapy in patients with cancer: is circulating DNA the answer?'. Annals of Translational Medicine, 2013 (1):24-25. [Details]
Saldova R, Struwe WB, Wynne K, Elia G, Duffy MJ, Rudd PM. (2013) 'Exploring the glycosylation of serum CA125'. International journal of molecular sciences, 14 (8):15636-15654. [Details]
Soletormos, G,Duffy, MJ,Hayes, DF,Sturgeon, CM,Barak, V,Bossuyt, PM,Diamandis, EP,Gion, M,Hyltoft-Petersen, P,Lamerz, RM,Nielsen, DL,Sibley, P,Tholander, B,Tuxen, MK,Bonfrer, JMG (2013) 'Design of Tumor Biomarker-Monitoring Trials: A Proposal by the European Group on Tumor Markers'. Clinical Chemistry, 59 :52-59. [DOI] [Details]
O Leary PC, Penny SA, Dolan RT, Kelly CM, Madden SF, Rexhepaj E, Brennan DJ, McCann AH, Pontén F, Uhlén M, Zagozdzon R, Duffy MJ, Kell MR, Jirström K, Gallagher WM (2013) 'Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer'. BMC Cancer, 13 . [DOI] [Details]
Duffy MJ (2013) 'The war on cancer: are we winning?'. Tumour Biology, 34 (3):1275-1284. [DOI] [Details]
Duffy MJ, Crown J (2013) 'Companion biomarkers: paving the pathway to personalized treatment for cancer'. Clinical Chemistry, 59 (10):1447-1456. [DOI] [Details]
Duffy MJ (2012) 'Tumor Markers in Clinical Practice: A Review Focusing on Common Solid Cancers'. Medycyna Pracy, . [DOI] [Details]
Brennan DJ, O'Connor DP, Laursen H, McGee SF, McCarthy S, Zagozdzon R, Rexhepaj E, Culhane AC, Martin FM, Duffy MJ, Landberg G, Ryden L, Hewitt SM, Kuhar MJ, Bernards R, Millikan RC, Crown JP, Jirstrom K, Gallagher WM (2012) 'The cocaine- and amphetamine-regulated transcript mediates ligand-independent activation of ERα, and is an independent prognostic factor in node-negative breast cancer'. Oncogene, 31 (30):3483-3494. [DOI] [Details]
Browne BC, Eustace AJ, Kennedy S, O'Brien NA, Pedersen K, McDermott MS, Larkin A, Ballot J, Mahgoub T, Sclafani F, Madden S, Kennedy J, Duffy MJ, Crown J, O'Donovan N (2012) 'Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours'. Breast Cancer Research and Treatment, . [DOI] [Details]
Sölétormos G, Duffy MJ, Hayes DF, Sturgeon CM, Barak V, Bossuyt PM, Diamandis EP, Gion M, Hyltoft-Petersen P, Lamerz RM, Nielsen DL, Sibley P, Tholander B, Tuxen MK, Bonfrer JM (2012) 'Design of Tumor Biomarker-Monitoring Trials: A Proposal by the European Group on Tumor Markers'. Clinical Chemistry, . [DOI] [Details]
McGowan PM, Mullooly M, Caiazza F, Sukor S, Madden SF, Maguire AA, Pierce A, McDermott EW, Crown J, O'Donovan N, Duffy MJ (2012) 'ADAM-17: a novel therapeutic target for triple negative breast cancer'. Annals of Oncology, . [DOI] [Details]
Duffy MJ, McGowan PM, Crown J (2012) 'Targeted therapy for triple-negative breast cancer: Where are we?'. International Journal of Cancer, 131 (11):2471-2477. [DOI] [Details]
Collins DM, O'Donovan N, McGowan PM, O'Sullivan F, Duffy MJ, Crown J (2012) 'Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines'. Annals of Oncology, 23 (7):1788-1795. [DOI] [Details]
Walsh S, Flanagan L, Quinn C, Evoy D, McDermott EW, Pierce A, Duffy MJ (2012) 'mTOR in breast cancer: differential expression in triple-negative and non-triple-negative tumors'. Breast, 21 (2):178-182. [DOI] [Details]
Duffy MJ, McGowan PM, Crown J (2012) 'Targeted therapy for triple-negative breast cancer: Where are we?'. International Journal of Cancer, 131 (11):2471-2477. [DOI] [Details]
Duffy MJ (2011) 'Prostate-specific antigen: does the current evidence support its use in prostate cancer screening?'. Clinical Biochemistry, 48 (Pt 4):310-316. [DOI] [Details]
Duffy MJ, van Rossum LG, van Turenhout ST, Malminiemi O, Sturgeon C, Lamerz R, Nicolini A, Haglund C, Holubec L, Fraser CG, Halloran SP; (2011) 'Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper'. International Journal of Cancer, 128 (1):3-11. [DOI] [Details]
Sturgeon CM, Duffy MJ, Walker G (2011) 'The National Institute for Health and Clinical Excellence (NICE) guidelines for early detection of ovarian cancer: the pivotal role of the clinical laboratory'. Annals of Clinical Biochemistry, 48 (Pt 4):295-299. [DOI] [Details]
Duffy MJ (2011) 'Prostate-specific antigen: does the current evidence support its use in prostate cancer screening?'. Annals of Clinical Biochemistry, 48 (Pt 4):310-316. [DOI] [Details]
Tryfonopoulos D, Walsh S, Collins DM, Flanagan L, Quinn C, Corkery B, McDermott EW, Evoy D, Pierce A, O'Donovan N, Crown J, Duffy MJ (2011) 'Src: a potential target for the treatment of triple-negative breast cancer'. Annals of Oncology, 22 (10):2234-2240. [DOI] [Details]
Duffy MJ, Mullooly M, O'Donovan N, Sukor S, Crown J, Pierce A, McGowan PM (2011) 'The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?'. Proteomics, 8 (1). [DOI] [Details]
McKiernan E, McDermott EW, Evoy D, Crown J, Duffy MJ (2011) 'The role of S100 genes in breast cancer progression'. Tumour Biology, 32 (3):441-450. [DOI] [Details]
Pierce A, Saldova R, Abd Hamid UM, Abrahams JL, McDermott EW, Evoy D, Duffy MJ, Rudd PM; (2010) 'Levels of specific glycans significantly distinguish lymph node-positive from lymph node-negative breast cancer patients'. Glycobiology, 20 (10):1283-1288. [DOI] [Details]
O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, Duffy MJ, Crown J, O'Donovan N, Slamon DJ.; (2010) 'Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib'. Molecular Cancer Therapy, 9 :1489-502. Available Online [Details]
Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, Bonfrer J, Ecke TH, Grossman HB, Hayes P, Hoffmann RT, Lerner SP, Löhe F, Louhimo J, Sawczuk I, Taketa K, Diamandis EP; National Academy of Clinical Biochemistry.; (2010) 'National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers'. Clinical Chemistry, 56 :e1-48. Available Online [Details]
Duffy MJ, Sturgeon C, Lamerz R, Haglund C, Holubec VL, Klapdor R, Nicolini A, Topolcan O, Heinemann V.; (2010) 'Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report'. Annnals of Oncology, 21 :441-447. Available Online [Details]
Browne BC, Crown J, Venkatesan N, Duffy MJ, Clynes M, Slamon D, O'Donovan N; (2010) 'Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells'. Annals of Oncology, . [DOI] [Details]
Duffy MJ, O'Donovan N, Crown J; (2010) 'Use of molecular markers for predicting therapy response in cancer patients'. Cancer Treatment Reviews, . [DOI] [Details]
Duffy MJ, Evoy D, McDermott EW; (2010) 'CA 15-3: uses and limitation as a biomarker for breast cancer'. Clinica chimica acta; international journal of clinical chemistry, 411 (23-24):1869-1874. [DOI] [Details]
Gallagher WM, Lau TY, Power KA, Dijon S, de Gardelle I, McDonnell S, Duffy MJ, Pennington SR, ; (2010) 'Prioritization of candidate protein biomarkers from an in vitro model system of breast tumor progression toward clinical verification'. Journal of Proteome Research, 9 (3):1450-1459. [DOI] [Details]
Rexhepaj E, Jirstrom K, O'Connor DP, O'Brien SL, Landberg G, Duffy MJ, Brennan DJ, Gallagher WM (2010) 'Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer'. BMC Cancer, 10 . [DOI] [Details]
Corcoran C, Friel AM, Duffy MJ, Crown J, O'Driscoll L; (2010) 'Intracellular and Extracellular MicroRNAs in Breast Cancer'. Clinical Chemistry, . [DOI] [Details]
Nicolini A, Ferrari P, Duffy MJ, Antonelli A, Rossi G, Metelli MR, Fulceri F, Anselmi L, Conte M, Berti P, Miccoli P (2010) 'Intensive risk-adjusted follow-up with the CEA, TPA, CA19.9, and CA72.4 tumor marker panel and abdominal ultrasonography to diagnose operable colorectal cancer recurrences: effect on survival'. Archives of Surgery, 145 (12):1177-1183. [DOI] [Details]
Sturgeon CM, Lai LC, Duffy MJ.; (2009) 'Serum tumour markers: how to order and interpret them'. BMJ (Clinical research ed.), 339 :b3527. Available Online [Details]
O'Donovan N, Browne BC, O'Brien N, Duffy MJ, Crown J, ; (2009) 'HER-2 signaling and inhibition in breast cancer'. Current Cancer Drug Targets, 3 (NA):419-438. [Details]
Gallagher WM, Lanigan F, McKiernan E, Brennan DJ, Hegarty S, Millikan RC, McBryan J, Jirstrom K, Landberg G, Martin F, Duffy MJ, ; (2009) 'Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer'. International Journal of Cancer, 124 (9):2088-2097. [DOI] [Details]
McGowan PM, Duffy MJ, McKiernan E, O'Donovan N, ; (2009) 'The role of ADAMs in disease pathophysiology'. Clinica Chimica Acta, 403 (1-2):31-36. [Details]
Martens JW, Span PN, Sieuwerts AM, Heuvel JJ, Spyratos F, Duffy MJ, Eppenberger-Castori S, Vacher S, O'Brien K, McKiernan E, Pierce A, Vuaroqueaux V, Foekens JA, Sweep FC, ; (2009) 'Harmonisation of multi-centre real-time reverse-transcribed PCR results of a candidate prognostic marker in breast cancer: an EU-FP6 supported study of members of the EORTC - PathoBiology Group'. European journal of Cancer, 45 (1):74-81. [DOI] [Details]
Schmitt M, Duffy MJ, Napieralski R, Martens JW, Span PN, Spyratos F, Sweep FC, Brunner N, Foekens JA, ; (2009) 'Methylated genes as new cancer biomarkers'. European journal of Cancer, 45 (3):335-346. [DOI] [Details]
McGowan PM, Duffy MJ, McKiernan E, O'Donovan N, ; (2009) 'Role of ADAMs in cancer formation and progression'. Clinical Cancer Research, 15 (4):1140-1144. [DOI] [Details]
Duffy MJ, Markey GC, Cullen R, Diggin P, Hill AD, Mc Dermott EW, O'Higgins NJ, ; (2009) 'Estrogen receptor-beta mRNA is associated with adverse outcome in patients with breast cancer'. Tumour Biology, 30 (4):171-175. [DOI] [Details]
Ryan BM, O'Donovan N, Duffy MJ.; (2009) 'Survivin: a new target for anti-cancer therapy'. Cancer Treatment Reviews, 35 :553-562. Available Online [Details]
McGowan PM, Duffy MJ; (2008) 'Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database'. Annals of Oncology, 19 (9):1566-1572. [DOI] [Details]
Gallagher WM, Duffy MJ, McGowan PM, ; (2008) 'Cancer invasion and metastasis: changing views'. Journal of Pathology, 3 (NA):283-293. [DOI] [Details]
Duffy MJ, McGowan PM, McKiernan E, Bolster F, Ryan BM, Hill AD, McDermott EW, Evoy D, O'Higgins N, Crown J, ; (2008) 'ADAM-17 predicts adverse outcome in patients with breast cancer'. Annals of Oncology, 6 (NA):1075-1081. [DOI] [Details]
Brennan, D. J., Hewitt, S. M., Rexhepaj, E., O¿Brien, S. L., McSherry, E., O¿Connor, D. P., Fagan, A., Culhane, A. C., Higgins, D. G., Jirstrom, K., Millikan, R. C., Landberg, G., Duffy, M. J., and Gallagher, W. M. ; (2008) 'Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer'. Clinical Cancer Research, 14 (9):2681-2689. [DOI] [Details]
Duffy MJ, McKiernan E, O'Brien K, Grebenchtchikov N, Geurts-Moespot A, Sieuwerts AM, Martens JW, Magdolen V, Evoy D, McDermott E, Crown J, Sweep FC, ; (2008) 'Protein kinase Cdelta expression in breast cancer as measured by real-time PCR, western blotting and ELISA'. Journal of Cancer, 99 (10):1644-1650. [DOI] [Details]
Crown J, Duffy MJ, ; (2008) 'A personalized approach to cancer treatment: how biomarkers can help'. Clinical Chemistry, 54 (11):1770-1779. [DOI] [Details]
Diamandis EP, Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, Babaian R, Bast RC Jr, Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee GG, Lamerz R, Looijenga LH, Molina R, Nielsen HJ, Rittenhouse H, Semjonow A, Shih IeM, Sibley P, Sölétormos G, Stephan C, Sokoll L, Hoffman BR, ; (2008) 'National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers'. Clinical Chemistry, 54 (12):1-79. [DOI] [Details]
Krajewska M, Kitada S, Winter JN, Variakojis D, Lichtenstein A, Zhai D, Cuddy M, Huang X, Luciano F, Baker CH, Kim H, Shin E, Kennedy S, Olson AH, Badzio A, Jassem J, Meinhold-Heerlein I, Duffy MJ, Schimmer AD, Tsao M, Brown E, Sawyers A, Andreeff M, Mercola D, Krajewski S, Reed JC; (2008) 'Bcl-B expression in human epithelial and nonepithelial malignancies'. Clinical Cancer Research, 14 (10):3011-3021. [DOI] [Details]
Duffy MJ, O'Donovan N, Brennan DJ, Gallagher WM, Ryan BM; (2007) 'Survivin: a promising tumor biomarker'. Cancer Letters, 249 (1):49-60. [DOI] [Details]
Duffy MJ, O'Brien N, O'Donovan N, Foley D, Hill AD, McDermott E, O'Higgins N, ; (2007) 'Use of a panel of novel genes for differentiating breast cancer from non-breast tissues'. Tumour Biology, 28 (6):312-317. [DOI] [Details]
Gallagher WM, Brennan DJ, Kelly C, Rexhepaj E, Dervan PA, Duffy MJ, ; (2007) 'Contribution of DNA and tissue microarray technology to the identification and validation of biomarkers and personalised medicine in breast cancer'. Cancer Genomics Proteomics, 3 (NA):121-134. [Details]
McGowan, PM, Ryan, BM, Hill, ADK, McDermott, E, OHiggins, N, Duffy, MJ, ; (2007) 'ADAM-17 expression in breast cancer correlates with variables of tumor progression'. Clinical Cancer Research, 13 :2335-2343. [Details]
Gallagher WM, Lau TY, O'Connor DP, Brennan DJ, Duffy MJ, Pennington SR, ; (2007) 'Breast cancer proteomics: clinical perspectives'. Expert Opinion on Biological Therapy, 2 (NA):209-219. [DOI] [Details]
Duffy, MJ, van Dalen, A, Haglund, C, Hansson, L, Holinski-Feder, E, Klapdor, R, Lamerz, R, Peltomaki, P, Sturgeon, C, Topolcan, O, ; (2007) 'Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use'. European journal of Cancer, 43 :1348-1360. [Details]
Culleton, J, OBrien, N, Ryan, BM, Hill, ADK, McDermott, E, OHiggins, N, Duffy, MJ, ; (2007) 'Lipophilin B: A gene preferentially expressed in breast tissue and upregulated in breast cancer'. International Journal of Cancer, 120 :1087-1092. [Details]
Browne, B, ODonovan, N, Venkatesan, N, Pegram, M, Clynes, M, Duffy, MJ, Crown, J, Slamon, DJ, ; (2007) 'The role of insulin-like growth factor I receptor (IGF-IR) in trastuzumab resistance in breast cancer cells'. Anticancer Research, 27 :1379-1379. [Details]
Duffy, MJ, ; (2007) 'Role of tumor markers in patients with solid cancers: A critical review'. European Journal of Internal Medicine, 18 :175-184. [Details]
OBrien, SL, Fagan, A, Fox, EJP, Millikan, RC, Culhane, AC, Brennan, DJ, McCann, AH, Hegarty, S, Moyna, S, Duffy, MJ, Higgins, DG, Jirstrom, K, Landberg, G, Gallagher, WM, ; (2007) 'CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer'. International Journal of Cancer, 120 :1434-1443. [Details]
Al-azawi D, Kelly G, Myers E, McDermott EW, Hill AD, Duffy MJ, Higgins NO; (2006) 'CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer'. BMC Cancer, 6 . [DOI] [Details]
Duffy MJ, Buggy Y, Maguire TM, McDermott E, Hill AD, O'Higgins N, ; (2006) 'Ets2 transcription factor in normal and neoplastic human breast tissue'. European journal of Cancer, 4 (NA):485-491. [DOI] [Details]
Brennan, DJ, Jirstrom, K, Kronblad, A, Millikan, RC, Landberg, G, Duffy, MJ, Ryden, L, Gallagher, WM, O'Brien, SL, ; (2006) 'CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance'. Clinical Cancer Research, 12 (21):6421-6431. [DOI] [Details]
Duffy MJ, ; (2006) 'Serum tumor markers in breast cancer: are they of clinical value?'. Clinical Chemistry, 3 (NA):345-351. [DOI] [Details]
Duffy MJ, ; (2006) 'Estrogen receptors: role in breast cancer'. Critical Reviews in Clinical Laboratory Sciences, 4 (NA):325-347. [DOI] [Details]
Duffy MJ, Ryan BM, Konecny GE, Kahlert S, Wang HJ, Untch M, Meng G, Pegram MD, Podratz KC, Crown J, Slamon DJ, ; (2006) 'Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1'. Annals of Oncology, 4 (NA):597-604. [DOI] [Details]
Savinov AY, Remacle AG, Golubkov VS, Krajewska M, Kennedy S, Duffy MJ, Rozanov DV, Krajewski S, Strongin AY; (2006) 'Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor beta correlates with the survival of breast cancer patients'. Cancer Research, 66 (5):2716-2724. [DOI] [Details]
Krajewska M, Kim H, Shin E, Kennedy S, Duffy MJ, Wong YF, Marr D, Mikolajczyk J, Shabaik A, Meinhold-Heerlein I, Huang X, Banares S, Hedayat H, Reed JC, Krajewski S; (2005) 'Tumor-associated alterations in caspase-14 expression in epithelial malignancies'. Clinical Cancer Research, 11 (15):5462-5471. [DOI] [Details]
Zwirner M, Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJ, Soletormos G, Torre GC, Tuxen MK, ; (2005) 'CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use'. International Journal of Gynecological Cancer, 5 (NA):679-691. [DOI] [Details]
Ryan, B, O'Donovan, N, Browne, B, O'Shea, C, Crown, J, Hill, ADK, McDermott, E, O'Higgins, N, Duffy, MJ, ; (2005) 'Expression of survivin and its splice variants survivin-2B and survivin-Delta Ex3 in breast cancer'. British Journal of Cancer, 92 (1):120-124. [DOI] [Details]
Gallagher WM, Brennan DJ, O'Brien SL, Fagan A, Culhane AC, Higgins DG, Duffy MJ, ; (2005) 'Application of DNA microarray technology in determining breast cancer prognosis and therapeutic response'. Expert Opinion on Biological Therapy, 8 (NA):1069-1083. [DOI] [Details]
Duffy MJ, ; (2005) 'Predictive markers in breast and other cancers: a review'. Clinical Chemistry, 3 (NA):494-503. [DOI] [Details]
Duffy MJ, Kelly LM, Buggy Y, Hill A, O'Donovan N, Duggan C, McDermott EW, O'Higgins NJ, Young L, ; (2005) 'Expression of the breast cancer metastasis suppressor gene, BRMS1, in human breast carcinoma: lack of correlation with metastasis to axillary lymph nodes'. Tumour Biology, 4 (NA):213-216. [DOI] [Details]
Grebenchtchikov N, Maguire TM, Riisbro R, Geurts-Moespot A, O'Donovan N, Schmitt M, McGreal G, McDermott E, O'Higgins N, Brünner N, Sweep CG, Duffy MJ (2005) 'Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration'. Oncology Reports, 14 (1):235-239. [Details]
Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, Goike H, Lamerz R, Nap M, Sölétormos G, Stieber P (2005) 'Tumor markers in breast cancer- European Group on Tumor Markers recommendations'. Tumour Biology, 26 (6):281-293. [DOI] [Details]
O'Brien NA, O'Donovan N, Ryan B, Hill AD, McDermott E, O'Higgins N, Duffy MJ; (2005) 'Mammaglobin a in breast cancer: existence of multiple molecular forms'. International Journal of Cancer, 114 (4):623-627. [DOI] [Details]
Roddam AW, Duffy MJ, Hamdy FC, Ward AM, Patnick J, Price CP, Rimmer J, Sturgeon C, White P, Allen NE; (2005) 'Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis'. EUR UROL, 48 (3):386-31. [DOI] [Details]
Troy AM, Sheahan K, Mulcahy HE, Duffy MJ, Hyland JM, O'Donoghue DP; (2004) 'Expression of Cathepsin B and L antigen and activity is associated with early colorectal cancer progression'. European journal of Cancer, 40 (10):1610-1616. [DOI] [Details]
Schmitt, M, Harbeck, N, Daidone, MG, Brunner, N, Duffy, MJ, Foekens, JA, Sweep, FCGJ, ; (2004) 'Identification, validation, and clinical implementation of tumor-associated biomarkers to improve therapy concepts, survival, and quality of life of cancer patients: Tasks of the Receptor and Biomarker Group of the European Organization for Research and Treatment of Cancer'. International Journal of Oncology, 25 (5):1397-1406. [Details]
Duffy, MJ,Duggan, C,Keane, R,Hill, ADK,McDermott, E,Crown, J,O'Higgins, N; (2004) 'High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: Study of 600 patients with histologically confirmed breast cancer'. Clinical Chemistry, 50 (NA):559-563. [DOI] [Details]
Duffy MJ, ; (2004) 'Evidence for the clinical use of tumour markers'. Annals of Clinical Biochemistry, Pt 5 (NA):370-377. [DOI] [Details]
Buggy, Y,Maguire, TM,McGreal, G,McDermott, E,Hill, ADK,O'Higgins, N,Duffy, MJ; (2004) 'Overexpression of the Ets-1 transcription factor in human breast cancer'. Journal of Cancer, 91 (NA):1308-1315. [DOI] [Details]
Duffy MJ, ; (2004) 'The urokinase plasminogen activator system: role in malignancy'. Current Pharmaceutical Design, 1 (NA):39-49. [Details]
Duffy, MJ, Duggan, C, ; (2004) 'The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer'. Clinical Biochemistry, 37 (7):541-548. [Details]
Look, M, van Putten, W, Duffy, M, Harbeck, N, Christensen, IJ, Thomssen, C, Kates, R, Spyratos, F, Ferno, M, Eppenberger-Castori, S, Sweep, CGJF, Ulm, K, Peyrat, JP, Martin, PM, Magdelenat, H, Brunner, N, Duggan, C, Lisboa, BW, Bendah, PO, Quillien, V, Daver, A, Ricolleau, G, Meijer-Van Gelder, M, Manders, P, Fiets, WE, Blankenstein, M, Broet, P, Romain, S, Daxenbichler, G, Windbichler, G, Cufer, T, Borstnar, S, Kueng, W, Beex, L, Klijn, J, O'Higgins, N, Eppenberger, U, Janicke, F, Schmitt, M, Foekens, J, ; (2003) 'Pooled analysis of prognostic impact of uPA and PAI-I in breast cancer patients'. Thrombosis and Haemostasis, 90 (3):538-548. [Details]
O'Donovan, N, Crown, J, Stunell, H, Hill, ADK, McDermott, E, O'Higgins, N, Duffy, MJ, ; (2003) 'Caspase 3 in breast cancer'. Clinical Cancer Research, 9 (2):738-742. [Details]
Greene, LM, Twal, WO, Duffy, MJ, McDermott, EW, Hill, AD, O'Higgins, NJ, McCann, A, Dervan, P, Argraves, W, Gallagher, WM, ; (2003) 'Elevated expression and altered processing of fibulin-1 protein in human breast cancer'. British Journal of Cancer, 88 (6):871-878. [Details]
Duffy MJ, O'Shea C, McKie N, Buggy Y, Duggan C, Hill AD, McDermott E, O'Higgins N, ; (2003) 'Expression of ADAM-9 mRNA and protein in human breast cancer'. International Journal of Cancer, 6 (NA):754-761. [DOI] [Details]
Duffy, MJ, van Dalen, A, Haglund, C, Hansson, L, Klapdor, R, Lamerz, R, Nilsson, O, Sturgeon, C, Topolcan, O, ; (2003) 'Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines'. European journal of Cancer, 39 (6):718-727. [Details]
Duffy, MJ, Lynn, DJ, Lloyd, AT, O'Shea, CM, ; (2003) 'The ADAMs family of proteins: from basic studies to potential clinical applications'. Thrombosis and Haemostasis, 89 (4):622-631. [Details]
Mofidi, R, Walsh, R, Ridgway, PF, Crotty, T, McDermott, EW, Keaveny, TV, Duffy, MJ, Hill, ADK, O'Higgins, N, ; (2003) 'Objective measurement of breast cancer oestrogen receptor status through digital image analysis'. European Journal of Surgical Oncology, 29 (1):20-24. [Details]
O'Brien N, Maguire TM, O'Donovan N, Lynch N, Hill AD, McDermott E, O'Higgins N, Duffy MJ; (2002) 'Mammaglobin a: a promising marker for breast cancer'. Clinical Chemistry, 48 (8):1362-1364. [Details]
Duffy MJ, ; (2002) 'Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies'. Clinical Chemistry, 8 (NA):1194-1197. [Details]
Duffy MJ, ; (2002) 'Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers'. Biochemical Society Transactions, 2 (NA):207-210. [DOI] [Details]
Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Fernö M, Eppenberger-Castori S, Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brünner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder ME, Manders P, Fiets WE, Blankenstein MA, Broët P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex LV, Klijn JG, O'Higgins N, Eppenberger U, Jänicke F, Schmitt M, Foekens JA (2002) 'Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients'. Journal of Cancer, 94 (2):116-128. [Details]
Price CP, Allard J, Davies G, Dawnay A, Duffy MJ, France M, Mandarino G, Ward AM, Patel B, Sibley P, Sturgeon C; (2001) 'Pre- and post-analytical factors that may influence use of serum prostate specific antigen and its isoforms in a screening programme for prostate cancer'. Clinical Biochemistry, 38 (Pt 3):188-216. [Details]
Cullen, R, Maguire, TM, McDermott, EW, Hill, ADK, O'Higgins, NJ, Duffy, MJ, ; (2001) 'Studies on oestrogen receptor-alpha and -beta mRNA in breast cancer'. European journal of Cancer, 37 (9):1118-1122. [Details]
Duffy MJ, ; (2001) 'Biochemical markers in breast cancer: which ones are clinically useful?'. Clinical Biochemistry, 5 (NA):347-352. [Details]
Duffy MJ, ; (2001) 'Clinical uses of tumor markers: a critical review'. Critical Reviews in Clinical Laboratory Sciences, 3 (NA):225-262. [Details]
Duffy MJ, ; (2001) 'Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?'. Clinical Chemistry, 4 (NA):624-630. [Details]
Cullen R, Maguire TM, McDermott EW, Hill AD, O'Higgins NJ, Duffy MJ; (2001) 'Studies on oestrogen receptor-alpha and -beta mRNA in breast cancer'. European journal of Cancer, 37 (9):1118-1122. [Details]
Cullen R, MaGuire T, Diggin P, Hill A, McDermott E, O'Higgins N, Duffy MJ; (2000) 'Detection of estrogen receptor-beta mRNA in breast cancer using RT-PCR'. International Journal of Biological Markers, 15 (1):114-115. [Details]
Maguire TM, Visser H, Toet K, McDermott E, O'Higgins N, Duffy MJ, Hanemaaijer R, Verheijen JH; (2000) 'Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors'. International Journal of Cancer, 86 (2):204-207. [Details]
O'Higgins N, Duffy MJ, Shering S, Sherry F, McDermott E, ; (2000) 'CA 15-3: a prognostic marker in breast cancer'. International Journal of Biological Markers, 4 (NA):330-333. [Details]
Duffy, MJ, Maguire, TM, Hill, A, McDermott, E, O'Higgins, N, ; (2000) 'Metalloproteinases: role in breast carcinogenesis, invasion and metastasis'. Breast Cancer Research, 2 (4):252-257. [Details]
Remacle A, McCarthy K, Noël A, Maguire T, McDermott E, O'Higgins N, Foidart JM, Duffy MJ (2000) 'High levels of TIMP-2 correlate with adverse prognosis in breast cancer'. International Journal of Cancer, 89 (2):118-121. [Details]
Maguire T, Chin D, Soutar D, Duffy MJ; (2000) 'Low levels of urokinase plasminogen activator components in basal cell carcinoma of the skin'. International Journal of Cancer, 85 (4):457-459. [Details]
McCarthy K, Maguire T, McGreal G, McDermott E, O'Higgins N, Duffy MJ; (1999) 'High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer'. International Journal of Cancer, 84 (1):44-48. [Details]
Duffy MJ, ; (1999) 'CA 15-3 and related mucins as circulating markers in breast cancer'. Annals of Clinical Biochemistry, (NA):579-586. [Details]
O'Higgins N, Duffy MJ, Maguire TM, McDermott EW, ; (1999) 'Urokinase plasminogen activator: a prognostic marker in multiple types of cancer'. Surgical Oncology, 2 (NA):130-135. [Details]
Maguire TM, Shering SG, Duggan CM, McDermott EW, O'Higgins NJ, Duffy MJ; (1998) 'High levels of cathepsin B predict poor outcome in patients with breast cancer'. International Journal of Biological Markers, 13 (3):139-144. [Details]
Duffy MJ, McCarthy K; (1998) 'Matrix metalloproteinases in cancer: prognostic markers and targets for therapy (review)'. International Journal of Oncology, 12 (6):1343-1348. [Details]
O'Higgins NJ, Duffy MJ, Duggan C, Mulcahy HE, McDermott EW, ; (1998) 'Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease'. Clinical Chemistry, 6 Pt 1 (NA):1177-1183. [Details]
Shering, SG, Sherry, F, McDermott, EW, O'Higgins, MJ, Duffy, MJ, ; (1998) 'Preoperative CA 15-3 concentrations predict outcome of patients with breast carcinoma'. Journal of Cancer, 83 (12):2521-2527. [Details]
Remacle AG, Noël A, Duggan C, McDermott E, O'Higgins N, Foidart JM, Duffy MJ (1998) 'Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer'. British Journal of Cancer, 77 (6):926-931. [Details]
Sweep CG, Geurts-Moespot J, Grebenschikov N, de Witte JH, Heuvel JJ, Schmitt M, Duffy MJ, Jänicke F, Kramer MD, Foekens JA, Brünner N, Brugal G, Pedersen AN, Benraad TJ (1998) 'External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts'. British Journal of Cancer, 78 (11):1434-1441. [Details]
Duffy MJ; (1998) 'Cancer metastasis: biological and clinical aspects'. Medicine, 167 (1):4-8. [Details]
Duffy MJ; (1998) 'CA 19-9 as a marker for gastrointestinal cancers: a review'. Clinical Biochemistry, 35 ( Pt 3) :364-370. [Details]
Kennedy S, Duffy MJ, Duggan C, Barnes C, Rafferty R, Kramer MD; (1998) 'Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry'. British Journal of Cancer, 77 (10):1638-1641. [Details]
Shering SG, Sherry F, McDermott EW, O'Higgins NJ, Duffy MJ; (1998) 'Preoperative CA 15-3 concentrations predict outcome of patients with breast carcinoma'. Journal of Cancer, 83 (12):2521-2527. [Details]
Skelly MM, Troy A, Duffy MJ, Mulcahy HE, Duggan C, Connell TG, O'Donoghue DP, Sheahan K; (1997) 'Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome'. Clinical Cancer Research, 3 (10):1837-1840. [Details]
Andreasen PA, Kjøller L, Christensen L, Duffy MJ (1997) 'The urokinase-type plasminogen activator system in cancer metastasis: a review'. International Journal of Cancer, 72 (1):1-22. [Details]
Duggan C, Kennedy S, Kramer MD, Barnes C, Elvin P, McDermott E, O'Higgins N, Duffy MJ; (1997) 'Plasminogen activator inhibitor type 2 in breast cancer'. British Journal of Cancer, 76 (5):622-627. [Details]
Maguire TM, Shering SG, McDermott EW, O'Higgins N, Fennelly JJ, Crown J, Duffy MJ; (1997) 'Assay of E-cadherin by ELISA in human breast cancers'. European journal of Cancer, 33 (3):404-408. [Details]
Duffy MJ, Duggan C; (1997) 'Re: urokinase and urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines'. Journal of Cancer, 89 (21):1628-1630. [Details]
Chenard MP, O'Siorain L, Shering S, Rouyer N, Lutz Y, Wolf C, Basset P, Bellocq JP, Duffy MJ; (1996) 'High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma'. International Journal of Cancer, 69 (6):448-451. [DOI] [Details]
Duffy MJ; (1996) 'The biochemistry of metastasis'. Clinical Chemistry, 32 :135-166. [Details]
Duffy MJ, Duggan C, Maguire T, Mulcahy K, Elvin P, McDermott E, Fennelly JJ, O'Higgins N; (1996) 'Urokinase plasminogen activator as a predictor of aggressive disease in breast cancer'. Enzyme, 49 (1-3):85-93. [Details]
Duffy MJ; (1996) 'Proteases as prognostic markers in cancer'. Clinical Cancer Research, 2 (4):613-618. [Details]
Duffy MJ; (1996) 'PSA as a marker for prostate cancer: a critical review'. Clinical Biochemistry, 33 ( Pt 6) :511-519. [Details]
Duffy MJ; (1995) 'Can molecular markers now be used for early diagnosis of malignancy?'. Clinical Chemistry, 41 (10):1410-1413. [Details]
Coveney EC, Geraghty JG, Sherry F, McDermott EW, Fennelly JJ, O'Higgins NJ, Duffy MJ; (1995) 'The clinical value of CEA and CA 15-3 in breast cancer management'. International Journal of Biological Markers, 10 (1):35-41. [Details]
Duffy MJ, Blaser J, Duggan C, McDermott E, O'Higgins N, Fennelly JJ, Tschesche H; (1995) 'Assay of matrix metalloproteases types 8 and 9 by ELISA in human breast cancer'. British Journal of Cancer, 71 (5):1025-1028. [Details]
Duggan C, Maguire T, McDermott E, O'Higgins N, Fennelly JJ, Duffy MJ; (1995) 'Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer'. International Journal of Cancer, 61 (5):597-600. [Details]
Duffy MJ, Reilly D, McDermott E, O'Higgins N, Fennelly JJ, Andreasen PA; (1994) 'Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer'. Journal of Cancer, 74 (8):2276-2280. [Details]
Sheahan K, Mulcahy HE, Duffy MJ, Gibbons D, McCarthy P, Parfrey NA, O'Donoghue DP, ; (1994) 'Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer'. Lancet, 344 (8922):583-584. [Details]
Nugent A, Gallagher J, Dolan J, O'Higgins N, Duffy MJ; (1994) 'Assay of the c-erbB-2 oncogene encoded protein by ELISA and immunocytochemistry in human breast cancer'. Clinical Biochemistry, 31 ( Pt 2) :171-173. [Details]
Reynolds JV, Sweeney JP, Nolan N, Korebrits A, Duffy MJ, McDermott EW, O'Higgins NJ; (1993) 'Management of ductal carcinoma in situ of the breast'. Medicine, 162 (2):45-48. [Details]
Duffy MJ; (1993) 'Cellular oncogenes and suppressor genes as prognostic markers in cancer'. Clinical Biochemistry, 26 (6):439-447. [Details]
Reilly DM, Andreasen PA, Duch M, Nolan N, Lecander I, Duffy MJ; (1992) 'Plasminogen activator inhibitor type 1 and 2 in human breast cancer'. Biochemical Society Transactions, 20 (1). [Details]
Duffy MJ; (1992) 'The role of proteolytic enzymes in cancer invasion and metastasis'. Clinical and Experimental Metastasis, 10 (3):145-155. [Details]
Duffy MJ; (1992) 'Inhibiting tissue invasion and metastasis as targets for cancer therapy'. Biotherapy, 4 (1):45-52. [Details]
Reilly D, Christensen L, Duch M, Nolan N, Duffy MJ, Andreasen PA; (1992) 'Type-1 plasminogen activator inhibitor in human breast carcinomas'. International Journal of Cancer, 50 (2):208-214. [Details]
Nugent A, McDermott E, Duffy K, O'Higgins N, Fennelly JJ, Duffy MJ; (1992) 'Enzyme-linked immunosorbent assay of c-erbB-2 oncoprotein in breast cancer'. Clinical Chemistry, 38 (8 Pt 1):1471-1474. [Details]
Duffy MJ, Reilly D, Brouillet JP, McDermott EW, Faul C, O'Higgins N, Fennelly JJ, Maudelonde T, Rochefort H; (1992) 'Cathepsin D concentration in breast cancer cytosols: correlation with disease-free interval and overall survival'. Clinical Chemistry, 38 (10):2114-2116. [Details]
Igoe D, Duffy MJ, McKenna TJ; (1992) 'TSH as an index of L-thyroxine replacement and suppression therapy'. Medicine, 161 (12):684-686. [Details]
Geraghty JG, Coveney EC, Sherry F, O'Higgins NJ, Duffy MJ; (1992) 'CA 15-3 in patients with locoregional and metastatic breast carcinoma'. Journal of Cancer, 70 (12):2831-2834. [Details]
Nugent A, McDermott E, O'Higgins N, Fennelly JJ, Duffy MJ; (1992) 'Measurement of erbB-2 oncoprotein in human breast cancers by ELISA'. Biochemical Society Transactions, 20 (1). [Details]
Reilly D, Andreasen P, Duffy MJ; (1991) 'Urokinase-type plasminogen activator and its inhibitor PAI-1 in breast cancer: studies at both protein and mRNA level'. Biochemical Society Transactions, 19 (1). [Details]
Duffy MJ, Brouillet JP, Reilly D, McDermott E, O'Higgins N, Fennelly JJ, Maudelonde T, Rochefort H; (1991) 'Cathepsin D concentration in breast cancer cytosols: correlation with biochemical, histological, and clinical findings'. Clinical Chemistry, 37 (1):101-104. [Details]
Reilly D, Andreasen PA, Duffy MJ; (1991) 'Urokinase-plasminogen activator in breast cancer: assay by both catalytic and immunoassay'. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2 (1):47-50. [Details]
Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ, Andreasen P; (1990) 'Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer'. Cancer Research, 50 (21):6827-6829. [Details]
Duffy MJ; (1990) 'Plasminogen activators and cancer'. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 1 (6):681-687. [Details]
Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ; (1990) 'Urokinase plasminogen activator and prognosis in breast cancer'. Lancet, 335 (8681). [Details]
Duffy MJ; (1990) 'Biochemical markers as prognostic indices in breast cancer'. Clinical Chemistry, 36 (2):188-191. [Details]
Cronin C, Igoe D, Duffy MJ, Cunningham SK, McKenna TJ; (1990) 'The overnight dexamethasone test is a worthwhile screening procedure'. Clinical Endocrinology, 33 (1):27-33. [Details]
Duffy MJ; (1989) 'New cancer markers'. Clinical Biochemistry, 26 ( Pt 5) :379-387. [Details]
Sheehan JD, Duffy MJ, Allen MA, Fennelly JJ; (1989) 'CA 125 as a tumour marker in epithelial ovarian cancer'. Medicine, 158 (1):10-13. [Details]
Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ, Lijnen HJ; (1988) 'Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report'. Journal of Cancer, 62 (3):531-533. [Details]
Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ, Lijnen HR; (1988) 'Tissue-type plasminogen activator, a new prognostic marker in breast cancer'. Cancer Research, 48 (5):1348-1349. [Details]
Johnston P, Dervan P, McAllister M, Duffy MJ, Carney DN; (1988) 'Immunohistochemical analysis of breast cancer oestrogen receptor status and its correlation with oestrogen receptor biochemical assay'. Medicine, 157 (7):226-228. [Details]
Duffy MJ; (1987) 'Do proteases play a role in cancer invasion and metastasis?'. European journal of Cancer, 23 (5):583-589. [Details]
Heaney JA, Allen MA, Keane T, Duffy MJ; (1987) 'Prostate-specific antigen. Superior serum marker for prostatic carcinoma'. Medicine, 156 (5):138-141. [Details]
Duffy MJ, O'Grady P, Simon J, Rose M, Lijnen HR; (1986) 'Tissue-type plasminogen activator in breast cancer: relationship with estradiol and progesterone receptors'. Journal of Cancer, 77 (3):621-623. [Details]
Duffy MJ, O'Siorain L, Waldron B, Smith C; (1986) 'Estradiol receptors in human breast carcinomas assayed by use of monoclonal antibodies'. Clinical Chemistry, 32 (10):1972-1974. [Details]
O'Grady P, Lijnen HR, Duffy MJ; (1985) 'Multiple forms of plasminogen activator in human breast tumors'. Cancer Research, 45 (12 Pt 1):6216-6218. [Details]
Duffy MJ, O'Sullivan F, McDonnell TJ, FitzGerald MX; (1985) 'Increased concentrations of the antigen CA-19-9 in serum of cystic fibrosis patients'. Clinical Chemistry, 31 (7):1245-1246. [Details]
Duffy MJ, O'Sullivan F, O'Donoghue D, Afdhal NH, Kelleher D; (1985) 'Ca-19-9, a new marker for gastrointestinal malignancy'. Medicine, 154 (10):385-386. [Details]
Duffy MJ, O'Grady P; (1984) 'Plasminogen activator and cancer'. European journal of Cancer, 20 (5):577-582. [Details]
Duffy MJ, O'Connell M, McDonnell L; (1984) 'Peroxidase activity as a marker for estrogen action in rat uteri and human mammary carcinomas'. Cancer Research, 91 :283-288. [Details]
Duffy MJ; (1984) 'A biochemical approach to cancer management'. Medicine, 153 (9):297-301. [Details]
Duffy MJ, O'Connell M, McDonnell L, Connolly CE, Cantwell B, Fennelly JJ, Conroy R; (1984) 'Studies on estradiol receptors in human mammary carcinomas'. Medicine, 153 (11):381-384. [Details]
Callan FP, Duffy MJ, Duffy GJ, Farrell RJ, McKenna TJ; (1983) 'Thyroid function in goitrous subjects with thyroxine binding globulin deficiency'. Acta Endocrinologica, 102 (4):527-530. [Details]
Duffy MJ, O'Connell M, O'Sullivan F, McKenna B, Allen MA, McDonnell L; (1983) 'CEA-like material in cytosols from human breast carcinomas. Correlation with biochemical and pathologic parameters'. Journal of Cancer, 51 (1):121-123. [Details]
Duffy MJ, Tuttlebee J, O'Sullivan F, Allen-Davis M; (1983) 'Evaluation of assays for thyroxine, triodotyronine and thyroid-stimulating hormone on the ARIA II automated radioimmunoassay instrument'. Journal of Automatic Chemistry, 5 (1):43-44. [DOI] [Details]
Farrell RJ, Duffy MJ, Duffy GJ; (1982) 'Serum fragment E and plasma beta-thromboglobulin in patients with acute pulmonary embolism and non-thromboembolic lung diseases'. Thrombosis Research, 27 (2):231-234. [Details]
Farrell RJ, Duffy MJ, Duffy GJ, Callan F, McKenna TJ; (1982) 'The free T3 index in familial TBG deficiency'. Clinica chimica acta; international journal of clinical chemistry, 118 (1):121-123. [Details]
Duffy MJ; (1982) 'Assay of estradiol receptors in human breast carcinomas using the gamma emitting ligand 16 alpha [125I]iodoestradiol'. Journal of Steroid Biochemistry, 16 (2):343-344. [Details]
O'Connell M, McDonnell L, Duffy MJ; (1982) 'Studies on nuclear estradiol receptors in human mammary carcinomas'. Clinica chimica acta; international journal of clinical chemistry, 119 (3):285-289. [Details]
Duffy MJ; (1982) 'Molecular biology in medicine'. Medicine, 151 (4):114-122. [Details]
Duffy MJ, O'Connell M, McDonnel L; (1982) 'Peroxidase activity in human breast carcinomas: correlation with histological and biochemical parameters'. European journal of Cancer, 18 (5):453-455. [Details]
Farrell RJ, Duffy MJ, Hynes N, Groarke Y, Drumm A, Ni Gogain N, Wilson A, Duffy GJ; (1982) 'Routine measurement of free thyroxine by a kinetic-based assay'. Irish Medical Journal, 75 (6):206-209. [Details]
Tobin MJ, Duffy MJ, Duffy G, FitzGerald MX; (1981) 'Serum immuno reactive trypsin and pancreatic isoamylase in older patients with cystic fibrosis'. Medicine, 150 (11):325-328. [Details]
Cantwell B, Duffy MJ, Mehigan JA, Fennelly JJ; (1981) 'Persisting and gross elevation of serum carcinoembryonic antigen levels after removal of tumour bulk'. Journal of Clinical Oncology, 7 (1):59-60. [Details]
Duffy MJ, O'Connell M; (1981) 'Estrogens, estradiol receptors and peroxidase activity in human mammary carcinomas'. European journal of Cancer, 17 (6):711-714. [Details]
Shridhar P, Duff FA, Kelly DG, Allen-Davis AM, Duffy MJ, Duffy GJ; (1981) 'Rectal examination and acid phosphatase'. Journal of Clinical Research, 283 (6289). [Details]
Duffy MJ; (1980) 'Measurement of progesterone receptors in human breast tumors using the synthetic progestin 16 alpha-ethyl-21-hydroxy-19-nor-4-pregnene-3,20-dione'. Journal of Steroid Biochemistry, 13 (9):1005-1007. [Details]
Cantwell B, Duffy MJ, Fennelly JJ, Jones M, Duffy G, Daly L; (1980) 'Carcino-embryonic antigen assay as a guide to tumour bulk, response to therapy and prognosis in human breast cancer'. Medicine, 149 (12):469-474. [Details]
Duffy MJ; (1980) 'Estradiol and progesterone receptors in human breast tumours'. Irish Medical Journal, 73 (8):311-312. [Details]
Farrell RJ, Duffy MJ, Moriarty MJ, Duffy GJ; (1980) 'Plasma concentrations of the platelet-specific beta-thromboglobulin in malignant disease'. British Journal of Cancer, 41 (6):989-991. [Details]
Duffy MJ, McGarry Y, Hynes N, Duffy GJ, Tobin MJ, Fitzgerald MX; (1980) 'Decreased immunoreactive trypsin levels in sera from cystic fibrosis patients'. Clinica chimica acta; international journal of clinical chemistry, 103 (2):233-235. [Details]
Hogan-Ryan A, Fennelly JJ, Jones M, Cantwell B, Duffy MJ; (1980) 'Serum sialic acid and CEA concentrations in human breast cancer'. British Journal of Cancer, 41 (4):587-592. [Details]
Duffy MJ, Duffy GJ; (1979) 'Studies on progesterone receptors in human breast carcionomas: use of natural and synthetic ligands'. European journal of Cancer, 15 (10):1181-1184. [Details]
Duffy MJ, Hynes N, Groarke Y, Oliver J, O'Broin A, Duffy G; (1978) 'Biochemical markers in breast carcinoma'. Irish Medical Journal, 71 (12):408-413. [Details]
Duffy MJ, Duffy GJ; (1978) 'Multiple steroid receptors in male breast carcinomas'. Clinica chimica acta; international journal of clinical chemistry, 85 (2):211-214. [Details]
Duffy MJ, Duffy GJ; (1978) 'Estradiol receptors in human liver'. Journal of Steroid Biochemistry, 9 (3):233-235. [Details]
Duffy MJ, Duffy GJ; (1977) 'Studies on the labeling of streptokinase with 99mTc for use as a radiopharmaceutical in the detection of deep-vein thrombosis: concise communication'. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 18 (5):483-485. [Details]
Duffy MJ, Duffy GJ; (1977) 'Estradiol receptors and glucose-6-phosphate dehydrogenase activity in human breast tumors'. Clinica chimica acta; international journal of clinical chemistry, 74 (2):167-171. [Details]
Duffy MJ, Duffy GJ; (1977) 'Measurement of estradiol receptors in human breast tumors by polyacrylamide gel electrophoresis'. Clinica chimica acta; international journal of clinical chemistry, 74 (2):161-166. [Details]
Duffy MJ, Duffy G; (1977) 'Peroxidase activity as a possible marker for a functional oestradiol receptor in human breast tumours [proceedings]'. Biochemical Society Transactions, 5 (6):1738-1739. [Details]
Duffy MJ, Mulhall D, Powell D; (1975) 'Subcellular distribution of substance P in bovine hypothalamus and substantia nigra'. Journal of Neurochemistry, 25 (3):305-307. [Details]
Sear CH, Duffy MJ; (1975) 'Efflux of cyclic AMP from resealed erythrocyte ghosts is not enhanced by Hepes'. Experientia, 31 (8):887-888. [Details]
Duffy MJ, Wong J, Powell D; (1975) 'Stimulation of adenylate cyclase activity in different areas of human brain by substance P'. Neuropharmacology, 14 (8):615-618. [Details]
Duffy MJ, Powell D; (1975) 'Stimulation of brain adenylate cyclase activity by the undecapeptide substance P and its modulation by the calcium ion'. Biochimica et biophysica acta, 385 (2):275-280. [Details]
Duffy MJ, Powell D; (1974) 'Letter: Cyclic A.M.P., substance P, and morphine analgesia'. Lancet, 2 (7892). [Details]
Duffy MJ, Schwarz V; (1974) 'Hormone and adenosine 3', 5' cyclic monophosphate stimulated phosphorylation of human erythrocyte membranes'. Biochemical Pharmacology, 23 (17):2464-2466. [Details]
Duffy MJ; (1974) 'Letter: Na+ transport defect in cystic fibrosis'. Nature, 249 (452):94-95. [Details]
Duffy MJ, Cohn EV, Schwarz V; (1974) 'Ca2+ uptake and binding by isolated erythrocyte membranes from cystic fibrosis and control subjects'. Clinica chimica acta; international journal of clinical chemistry, 50 (1):97-101. [Details]
Duffy MJ, Schwarz V; (1973) 'Cyclic AMP stimulated phosphorylation of erythrocyte membranes from cystic fibrosis and control subjects'. Clinica chimica acta; international journal of clinical chemistry, 49 (3):397-399. [Details]
Duffy MJ, Schwarz V; (1973) 'Calcium binding by the erythrocyte membrane'. Biochimica et biophysica acta, 330 (3):294-301. [Details]
Duffy MJ, Comer D, Schwarz V; (1973) 'Serum binding of Ca2+ and cystic fibrosis'. Nature: New biology, 246 (153). [Details]
Lloyd G, Dacie JE, Duffy MJ; (1973) 'Axial tomography of the orbits and paranasal sinuses'. British Journal of Radiology, 46 (542). [Details]
Duffy MJ, Schwarz V; (1972) 'Cystic fibrosis and membrane transport'. Lancet, 2 (7768):136-137. [Details]
Duffy MJ, Schwarz V; (1972) 'Phosphorylation of the erythrocyte membrane: stimulation by adenosine 3':5'-cyclic monophosphate'. Biochemical Journal, 126 (3):1-1. [Details]
Dolly JO, Dillon A, Duffy MJ, Fottrell PF; (1971) 'Further studies on multiple forms of peptidases in mammalian tissues including intestinal mucosa from children with treated and untreated coeliac disease'. Clinica chimica acta; international journal of clinical chemistry, 31 (1):55-62. [Details]
 

Conference Publications

Brennan, DJ,Rexhepaj, E,O'Brien, SL,McSherry, E,O'Connor, DP,Fagan, A,Culhane, AC,Higgins, DG,Jirstrom, K,Millikan, RC,Landberg, G,Duffy, MJ,Hewitt, SM,Gallaghe, WM (2008) CLINICAL CANCER RESEARCH Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer , pp.2681-2689 [DOI] [Details]
Ryan, BM,Konecny, GE,Kahlert, S,Wang, HJ,Untch, M,Meng, G,Pegram, MD,Podratz, KC,Crown, J,Slamon, DJ,Duffy, MJ (2006) ANNALS OF ONCOLOGY Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1 , pp.597-604 [DOI] [Details]
Duffy, MJ (2002) BIOCHEMICAL SOCIETY TRANSACTIONS Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers , pp.207-210 [Details]
Duffy, MJ,Shering, S,Sherry, F,McDermott, E,O'Higgins, N (2000) INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS CA 15-3: a prognostic marker in breast cancer , pp.330-333 [Details]
Cullen, R,Maguire, T,Diggin, P,Hill, A,McDermott, E,O'Higgins, NO,Duffy, MJ (2000) INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS Detection of estrogen receptor-beta mRNA in breast cancer using RT-PCR , pp.114-115 [Details]
ODWYER, PJ,DUFFY, MJ,OSULLIVAN, F,MCDERMOTT, E,LOSTY, P,OHIGGINS, NJ (1990) WORLD JOURNAL OF SURGERY CEA AND CA 15-3 IN PRIMARY AND RECURRENT BREAST-CANCER , pp.562-566 [Details]
                                                                                         

Research

Research Interests

Our research focuses on the identification and validation of new biomarkers and therapeutic targets for breast cancer. This work is being carried out in collaboration with BREAST-PREDICT members, based in University College Dublin, Dublin City University, Royal College of Surgeons in Ireland  and Trinity College, Dublin.

In addition, we have ongoing collaboration with investigators at the University of Los Angeles, California (UCLA), University of Oxford and University of Cambridge and the Karolinska Institute. 

UCD Medicine Research Theme: Translational Oncology 

Research Projects

Sponsor : Health Research Board (HRB)
Title : "Breast Cancer Metastasis: Biomarkers and functional mediators" research programme
Start Date / End Date : 01-OCT-05 / 30-SEP-10
Sponsor : Health Research Board (HRB)
Title : Role of ADAMS in Breast Cancer
Start Date / End Date : 01-OCT-02 / 30-SEP-02
Sponsor : Irish Research Council for Science Engineering and Technology (IRCSET)
Title : Mr. James Murphy
Start Date / End Date : 01-OCT-02 / 30-SEP-05
Sponsor : Irish Research Council for Science Engineering and Technology (IRCSET)
Title : Ms. Jane Culleton
Start Date / End Date : 01-OCT-02 / 30-SEP-05
Sponsor : Irish Research Council for Science Engineering and Technology (IRCSET)
Title : Survival in Breast Cancer (Ms. Brid Ryan)
Start Date / End Date : 01-OCT-02 / 30-SEP-04
Sponsor : Cancer Research Ireland (CRI)
Title : Mammaglobin as a marker for breast cancer
Start Date / End Date : 01-OCT-03 / 31-MAR-07
Sponsor : European Commission FP6
Title : Epigenetic profiling of breast cancer: prognostic and therapeutic applications
Start Date / End Date : 01-JAN-04 / 31-DEC-06
Sponsor : Randox Laboratories Ltd
Title : Evaluation of a breast cancer DNA chip
Start Date / End Date : 01-JAN-07 / 31-DEC-07
Sponsor : Irish Cancer Society (ICS)
Title : Collaborative Cancer Research Centre: From population to patient: Leveraging systems medicine to personalise breast cancer treatment (ICS BREAST PREDICT)
Start Date / End Date : 01-OCT-13 / 30-SEP-18
Sponsor : University College Dublin Foundation Ltd.
Title : Post-doctoral Researcher
Start Date / End Date : 01-NOV-13 / 31-DEC-16
Sponsor : Irish Cancer Society (ICS)
Title : The role of ADAMs in mediating resistance to HER-targeted therapies
Start Date / End Date : 01-DEC-11 / 23-OCT-15
Sponsor : The Wellcome Trust (WT)
Title : The role of ADAMs in mediating resistance to anti-HER agents
Start Date / End Date : 04-JUN-13 / 26-JUL-13
Sponsor : University College Dublin (UCD)
Title : ADAM10: A NEW PLAYER IN BREAST CANCER PROGRESSION?
Start Date / End Date : 01-MAY-12 / 31-OCT-13
Sponsor : Science Foundation Ireland (SFI)
Title : Molecular therapeutics for cancer: translational research to individualise therapy with targeted agents
Start Date / End Date : 01-OCT-09 / 31-MAR-15
 

Current Postgraduate Students

Naoise Synnott, Doctor of Philosophy (PhD)   -   Thesis Supervisor

Teaching

Teaching Philosophy

 Cancer biology to BSc Hons course in Biochemistry and Pharmacology.

 Tumor biomarkers to postgraduate Nursing students  


         

Collaborators

Internal Collaborators

Mr Enda McDermott, St Vincent's University Hospital,

Professor John Crown, St Vincent's University Hospital,

Professor Liam Gallagher, UCD

Dr Norma O'Donovan, DCU

External Collaborators

Dr Neil O'Brien and Professor Denis Slamon, UCLA, Los Angeles
 
Prof G. Murphy, University of Cambridge 
 
Dr A Kong, University of Oxford 
 
Sir Professor Alan Fersht, University of Cambridge 
 
Professor Klas Wiman, Karolinska Institute, Stockholm